Oraya TherapyTM Stereotactic Radiotherapy for Wet AMD


Hospital receives awards nomination for work with innovative eye therapy
The Ophthalmology team at Heart of England NHS Foundation Trust is celebrating after it was shortlisted for a prestigious award for its work with an innovative treatment which has proved life-changing for sufferers of a chronic eye disease…Read Press Release >

Oraya Therapeutics’ IRay® Radiotherapy System Wins Silver at 2015 Medical Design Excellence Awards

Device for treating wet age-related macular degeneration honored for design and innovation…Read Press Release >

U.K. Ophthalmologists Lead in Treatment of Wet AMD Patients with Oraya Therapy Across Europe

U.K. ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet age-related macular degeneration (AMD)…Read Press Release >

Treatment Locations



Kent residents with wet age-related macular degeneration (AMD) now have access to the Oraya Therapy at the Kent Institute of Medicine and Surgery (KIMS) in Maidstone. The hospital has recently begun treating patients. The treatment is carried out by one of KIMS’ highly skilled team of ophthalmologists. For more information in the UK, call 0800-690-6495.


Oraya Therapeutics’ AMD Radiotherapy Device Receives New Indication of Use for Choroidal Metastases

Read Press Release >

Carl Zeiss Meditec and Oraya Therapeutics sign collaboration agreement

Read ZEISS Press Release >

Three-year Data from INTREPID Study Shows Favorable Safety Profile — Commercial Adoption of Oraya Therapy Continues to Grow.

Read Press Release >

Special Event at House of Commons


Leading organizations and Members of Parliament come together at a special event sponsored by Oraya Therapeutics. More >

AMD Alliance International leads an event at the House of Commons addressing current issues with diagnosing, treating and managing the growing number of aging people affected by age-related macular degeneration (AMD), the leading cause of blindness in the western world.


Sir David Amess hosts a parliamentary event about age-related macular degeneration (AMD). More >

BBC Look North – September 2014


Press Release: First National Health Service hospital in UK and four prestigious hospitals in Germany adopt Oraya Therapy to maintain vision with reduced anti-VEGF injections.
More >

News-Medical.net – September 2014


Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics. More >


Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment.   More >


Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD.  More >


Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye.  More >


Published Articles
Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: Year 2 Results of the INTREPID Study

Published in Ophthalmology, January 2015.
Free Download >

Stereotatic Radiotherapy for Wet Age-Related Macular Degeneration (INTREPID): Influence of Baseline Characteristics on Clinical Response

Published in RETINA, February 2015. Download >

Treating Neovascular AMD

Published in Expert Reviews of Ophthalmology, 2014. Download >

© 2015 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.